What Have Monoclonal Antibodies Ever Done for Us? Past, Present and Future Perspectives on Antibodies and How They Have Driven Bioprocessing Progress
Paul Varley, PhD
SVP, Development, Alchemab Therapeutics
Extracellular Vesicles as Promising Drug Modalities in Spinal Cord Injury and Other (Neuro-)Degenerative Diseases
Eva Rohde, M.D.
Chair, Transfusion Medicine, Director GMP Unit, Spinal Cord Injury and Tissue Regeneration Center Salzburg (SCI-TReCS), Paracelsus Medical University Salzburg